432 related articles for article (PubMed ID: 32937821)
1. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
2. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
3. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
Thummuri D; Naidu VGM; Chaudhari P
J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
[TBL] [Abstract][Full Text] [Related]
4. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
Qiang YW; Chen Y; Stephens O; Brown N; Chen B; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2008 Jul; 112(1):196-207. PubMed ID: 18305214
[TBL] [Abstract][Full Text] [Related]
5. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
8. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
9. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
10. [The role of RANK/RANKL and OPG in multiple myeloma].
Zdzisińska B; Kandefer-Szerszeń M
Postepy Hig Med Dosw (Online); 2006; 60():471-82. PubMed ID: 17013366
[TBL] [Abstract][Full Text] [Related]
11. Glycyrrhizin Suppresses RANKL-Induced Osteoclastogenesis and Oxidative Stress Through Inhibiting NF-κB and MAPK and Activating AMPK/Nrf2.
Li Z; Chen C; Zhu X; Li Y; Yu R; Xu W
Calcif Tissue Int; 2018 Sep; 103(3):324-337. PubMed ID: 29721581
[TBL] [Abstract][Full Text] [Related]
12. Schisandrin A restrains osteoclastogenesis by inhibiting reactive oxygen species and activating Nrf2 signalling.
Ni S; Qian Z; Yuan Y; Li D; Zhong Z; Ghorbani F; Zhang X; Zhang F; Zhang Z; Liu Z; Yu B
Cell Prolif; 2020 Oct; 53(10):e12882. PubMed ID: 32871020
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
14. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
15. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
Hyeon S; Lee H; Yang Y; Jeong W
Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
[TBL] [Abstract][Full Text] [Related]
16. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
17. RANKL induces Bach1 nuclear import and attenuates Nrf2-mediated antioxidant enzymes, thereby augmenting intracellular reactive oxygen species signaling and osteoclastogenesis in mice.
Kanzaki H; Shinohara F; Itohiya K; Yamaguchi Y; Katsumata Y; Matsuzawa M; Fukaya S; Miyamoto Y; Wada S; Nakamura Y
FASEB J; 2017 Feb; 31(2):781-792. PubMed ID: 27836987
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
19. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
Colucci S; Brunetti G; Rizzi R; Zonno A; Mori G; Colaianni G; Del Prete D; Faccio R; Liso A; Capalbo S; Liso V; Zallone A; Grano M
Blood; 2004 Dec; 104(12):3722-30. PubMed ID: 15308561
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation.
Yamaguchi Y; Kanzaki H; Katsumata Y; Itohiya K; Fukaya S; Miyamoto Y; Narimiya T; Wada S; Nakamura Y
J Cell Mol Med; 2018 Feb; 22(2):1138-1147. PubMed ID: 29063666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
